Prevalence of asthma and atopy in sarcoidosis
Article first published online: 24 JAN 2012
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology
Volume 17, Issue 2, pages 285–290, February 2012
How to Cite
WILSHER, M., HOPKINS, R., ZENG, I., CORNERE, M. and DOUGLAS, R. (2012), Prevalence of asthma and atopy in sarcoidosis. Respirology, 17: 285–290. doi: 10.1111/j.1440-1843.2011.02066.x
- Issue published online: 24 JAN 2012
- Article first published online: 24 JAN 2012
- Accepted manuscript online: 22 SEP 2011 08:46AM EST
- Received 18 January 2011; invited to revise 4 March 2011, 17 June 2011; revised 11 May 2011, 14 July 2011; accepted 29 August 2011 (Associate Editor: Yuben Moodley).
Background and objective: We hypothesized that the prevalence of allergic disorders, characterized by the release of type 2 cytokines (IL-4, IL-5, IL-10), would be lower in sarcoidosis in which there is a dominant type 1 immune response (IL-2, interferon-gamma). The objective was to measure the prevalence of atopy and self-reported asthma in patients with sarcoidosis.
Methods: Sarcoidosis patients (n = 136, 72 M, age range 22–75), recruited in the outpatient setting, completed a modified European Community Respiratory Health Survey. 123 of these patients provided blood for allergy testing.
Results: For the cohort as a whole the self-reported prevalence of asthma ever (21.5%) and asthma attack in the last 12 months (7.5%), was high as was wheezing (42.1%), breathlessness with wheeze (22.3%) and use of an asthma medication (13.1%). The prevalence of atopy was 34%. These data are not different from the previously reported prevalence of asthma and atopy in New Zealand.
Conclusions: The same prevalence of asthma symptoms and atopy as in the normal population suggests that the immune system is not skewed away from mounting T helper type 2 immune responses in sarcoidosis.